Gut microbiota key to variability in statin response
Today, 25%-30% of people over the age of 40-50 in Europe and the United States take statins. However, variability between patients in their response to treatment remains a challenge for clinicians. Can the characteristics of patients’ gut microbiota help us predict and manage this variability?
